[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.166.22. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 274
Citations 0
Comment & Response
June 2014

Methylation Analysis in Newborn Screening for Fragile X Syndrome—Reply

Author Affiliations
  • 1Department of Biochemistry and Molecular Medicine, MIND Institute, University of California, Davis, School of Medicine
JAMA Neurol. 2014;71(6):800-801. doi:10.1001/jamaneurol.2014.454

In Reply In their response letter to an article in JAMA Neurology on newborn screening for fragile X syndrome, Godler and collaborators stated that there is a “contentious ethical issue [in] the detection of late-onset [premutation] conditions” (eg, fragile X–associated tremor/ataxia syndrome and fragile X–associated primary ovarian insufficiency) in infant carriers. However, newborn screening does not detect late-onset conditions, rather it only identifies the allele size of the FMR1 gene. From the most recent large screening studies,1,2 most of the identified carriers had alleles with low CGG repeat number, which are associated with relatively low risk for developing one of the late-onset conditions.

First Page Preview View Large
First page PDF preview
First page PDF preview
×